MedTrace Logo

Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State

NCT05739851 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-02-22

No results posted yet for this study

Summary

This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229\_01(2.5/500 mg) at fasting state.

Conditions

  • Healthy

Interventions

DRUG

DA-1229_01 2.5/500mg (Before)

single dose administration (one tablet once a day)

DRUG

DA-1229_01 2.5/500mg (After)

single dose administration (one tablet once a day)

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-18
Primary Completion
2023-04-14
Completion
2023-04-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05739851 on ClinicalTrials.gov